Dietary Supplementation with Highly Unsaturated Fatty Acids: Implications for Interventions with Persons with Mental Retardation from Research on Infant Cognitive Development, ADHD, and Other Developmental Disabilities

International Review of Research in Mental Retardation

Volumn 32, Issue , 2006, Pages 159-196

  Sinn, Natalie ^a   Wilson, Carlene ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33750208094     PISSN: 00747750     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7750(06)32006-X     Document Type: Review

References (157)

1. Adams P.B., Lawson S., Sanigorski A., and Sinclair A.J. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 31 Suppl. (1996) S157-S161
2. Aman M.G., Buican B., and Arnold L.E. Methylphenidate treatment in children with borderline IQ and mental retardation: Analysis of three aggregated studies. Journal of Child and Adolescent Psychopharmacology 13 (2003) 29-40
3. Aman M.G., Kern R.A., McGhee D.E., and Arnold L.E. Fenfluramine and methylphenidate in children with mental retardation and attention deficit hyperactivity disorder: Laboratory effects. Journal of Autism and Developmental Disorders 23 (1993) 491-506
4. Aman M.G., Pejeau C., Osborne P., Rojahn J., and Handen B.L. Four-year follow-up of children with low intelligence and ADHD. Research in Developmental Disabilities 17 (1996) 417-432
5. Anderson J.W., Johnstone B.M., and Remley D.T. Breast-feeding and cognitive development: A meta-analysis. American Journal of Clinical Nutrition 70 (1999) 525-535
6. Arnold L.E. Potential link between dietary intake of fatty acids and behavior: Pilot exploration of serum lipids in attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology 4 3 (1994) 171-182
7. Arnold L.E., Kleykamp D., Votolato N.A., Taylor W.A., Kontras S.B., and Tobin K. Gamma-linolenic acid for attention-deficit hyperactivity disorder: Placebo-controlled comparison to d-amphetamine. Biological Psychiatry 25 (1989) 222-228
8. Arvindakshan M., Ghate M., Ranjekar P., Evans D.R., and Mahadik S.P. Supplementation with a combination of w-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophrenia Research 62 (2003) 195-204
9. Baker S.M. A biochemical approach to the problem of dyslexia. Journal of Learning Disabilities 18 10 (1985) 581-584
10. Baumeister A.A., and Bacharach V.R. A critical analysis of the infant health and development program. Intelligence 23 (1996) 79-104
11. Bekaroglu M., Aslan Y., Gedik Y., Deger O., Mocan H., Erduran E., et al. Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: A research note. Journal of Child Psychology and Psychiatry 37 2 (1996) 225-227
12. Bell J.G., Sargent J.R., Tocher D.R., and Dick J.R. Red blood cell fatty acid compositions in a patient with autistic spectrum disorder: A characteristic abnormality in neurodevelopmental disorders?. Prostaglandins, Leukotrienes and Essential Fatty Acids 63 2-1 (2000) 21-25
13. Bell J.G., MacKinlay E.E., Dick J.R., MacDonald D.J., Boyle R.M., and Glen A.C.A. Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins, Leukotrienes and Essential Fatty Acids 71 (2004) 201-204
14. Benton D. Micro-nutrient supplementation and the intelligence of children. Neuroscience & Biobehavioral Reviews 25 (2001) 297-309
15. Biederman J. ADHD across the lifecycle. Biological Psychiatry 42 (1997) 146S
16. Bihm E.M., Poindexter A.R., and Warren E.R. Aggression and psychopathology in persons with severe or profound mental retardation. Research in Developmental Disabilities 19 5 (1998) 423-438
17. Bilici M., Yildirim F., Kandil S., Bekaroglu M., Yildirmis S., Deger O., et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 28 (2004) 181-190
18. Birch E., Garfield S., Hoffman D., Uauy R., and Birch D. A randomised controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Developmental Medicine and Child Neurology 42 (2000) 174-181
19. Black M.M. Micronutrient deficiencies and cognitive functioning. Journal of Nutrition 133 (2003) 3927S-3931S
20. Breslau N., Chilcoat H., DelDotto J., Andreski P., and Brown G. Low birth weight and neurocognitive status at six years of age. Biological Psychiatry 40 (1996) 389-397
21. Broadhurst C.L., Wang Y., Crawford M.A., Cunnane S.C., Parkington J.E., and Schmidt W.F. Brain-specific lipids from marine, lacustrine, or terrestrial food resources: Potential impact on early African Homo sapiens. Comparative Biochemistry and Physiology Part B 131 (2002) 653-673
22. Bryan J., and Hughes D. Polyunsaturated fatty acids. The effects of nutrition on cognitive performance in children (2002), Unilever, Nederland B.V.
23. Bryan J., Osendarp S., Hughes D., Calvaresi E., Baghurst K., and van Klinken J.-W. Nutrients for cognitive development in school-aged children. Nutrition Reviews 62 8 (2004) 295-306
24. Burgess J.R., Stevens L.J., Zhang W., and Peck L. Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. American Journal of Clinical Nutrition 71 1 (2000) 327-330
25. Buydens-Branchey L., Branchey M., McMakin D.L., and Hibbeln J.R. Polyunsaturated fatty acid status and aggression in cocaine addicts. Drug and Alcohol Dependence 71 (2003) 319-323
26. Camp B.W., Broman S.H., Nichols P.L., and Leff M. Maternal and neonatal risk factors for mental retardation: Defining the "at-risk" child. Early Human Development 50 (1998) 159-173
27. Carlson S.E., and Neuringer M. Polyunsaturated fatty acid status and neurodevelopment: A summary and critical analysis of the literature. Lipids 34 2 (1999) 171-178
28. Castellví-Bel S., and Milà M. Genes responsible for nonspecific mental retardation. Molecular Genetics and Metabolism 72 (2001) 104-108
29. Chabot R.J., di Michele F., Prichep L., and John E.R. The clinical role of computerized EEG in the evaluation and treatment of learning and attention disorders in children and adolescents. Journal of Neuropsychiatry and Clinical Neuroscience 13 (2001) 171-186
30. Chalon S., Vancassel S., Zimmer L., Guilloteau D., and Durand G. Polyunsaturated fatty acids and cerebral function: Focus on monoaminergic neurotransmission. Lipids 36 9 (2001) 937-944
31. Chechlacz M., and Gleeson J.G. Is mental retardation a defect of synapse structure and function?. Pediatric Neurology 29 1 (2003) 11-17
32. Chen J.R., Hsu S.F., Hsu C.D., Hwang L.H., and Yang S.C. Dietary patterns and blood fatty acid composition in children with attention-deficit hyperactivity disorder in Taiwan. Journal of Nutritional Biochemistry 15 (2004) 467-472
33. Chiu C.C., Huang S.Y., Su K.P., Lu M.L., Huang M.C., Chen C.C., et al. Polyunsaturated fatty acid deficit in patients with bipolar mania. European Neuropsychopharmacology 13 (2003) 99-103
34. Colquhoun I., and Bunday S. A lack of essential fatty acids as a possible cause of hyperactivity in children. Medical Hypotheses 7 (1981) 673-679
35. Das J.P., and Melnyk L. Attention Checklist: A scale for mildly mentally handicapped adolescents. Psychological Reports 64 (1989) 1267-1274
36. Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder. NIH Consensus Statement Online November 16-18, cited 2005, March 31 16 (1998). http://consensus.nih.gov/1998/1998AttentionDeficitHyperactivityDisorder1 10html.htm (2)
37. Dunstan J.A., Mori T.A., Barden A., Beilin L.J., Holt P.G., Calder P.C., et al. Effects of n-3 polyunsaturated fatty acid supplementation in pregnancy on maternal and fetal erythrocyte fatty acid composition. European Journal of Clinical Nutrition 58 3 (2004) 429-437
38. Dutta-Roy A.K. Fatty acid transport and metabolism in the feto-placental unit and the role of fatty acid-binding proteins. Nutritional Biochemistry 8 (1997) 548-557
39. Edelstein T.M., and Glenwick D.S. Referral reasons for psychological services for adults with mental retardation. Research in Developmental Disabilities 18 1 (1997) 45-59
40. Edwards R., Peet M., Shay J., and Horrobin D.F. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. Journal of Affective Disorders 48 (1998) 149-155
41. Erasmus U. Fats that heal, fats that kill. 2nd ed. (1993), Alive Books, Burnaby BC Canada
42. Feingold B.F. Why is your child hyperactive? (1975), Random House, New York
43. Fenton W.S., Dickerson F., Boronow J., Hibbeln J.R., and Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. American Journal of Psychiatry 158 (2001) 2071-2074
44. Friedland R.P. Fish consumption and the risk of Alzheimer Disease. Archives of Neurology 60 (2003) 923-924
45. Gamoh S., Hashimoto M., Sugioka K., Hossain M.S., Hata N., Misawa Y., et al. Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience 93 1 (1999) 237-241
46. Gesch C.B., Hammond S.M., Hampson S.E., Eves A., and Crowder M.J. Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. The British Journal of Psychiatry 181 (2002) 22-28
47. Gibson R.A., Neumann M.A., and Makrides M. Effect of dietary docosahexaenoic acid on brain composition and neural function in term infants. Lipids 31 (1996) S177-S181
48. Gibson R.A., Neumann M.A., and Makrides M. Effect of increasing breast milk docosahexaenoic acid on plasma and erythrocyte phospholipid fatty acids and neural indices of exclusively breast fed infants. European Journal of Clinical Nutrition 51 9 (1997) 578-584
49. Haag M. Essential fatty acids and the brain. Canadian Journal of Psychiatry 48 3 (2003) 195-203
50. Haglund O., Wallin R., Wretling S., Hultberg B., and Saldeen T. Effects of fish oil alone and combined with long chain (n-6) fatty acids on some coronary risk factors in male subjects. The Journal of Nutritional Biochemistry 9 (1998) 629-635
51. Hallahan B., and Garland M.R. Essential fatty acids and their role in the treatment of impulsivity disorders. Prostaglandins, Leukotrienes and Essential Fatty Acids 71 (2004) 211-216
52. Hamazaki T., Sawazaki S., Itomura M., Asaoka E., Nagao Y., Nishimura N., et al. The effect of docosahexaenoic acid on aggression in young adults: A placebo controlled double-blind study. Journal of Clinical Investigation 97 4 (1996) 1129-1134
53. Hamilton J., Greiner R., Salem Jr. N., and Kim H.Y. n-3 fatty acid deficiency decreases phosphatidylserine accumulation selectively in neuronal tissues. Lipids 35 8 (2000) 863-869
54. Handen B.L., Janosky J., and McAuliffe S. Long-term follow-up of children with mental retardation/borderline intellectual functioning and ADHD. Journal of Abnormal Child Psychology 25 (1997) 287-295
55. Harrell R.F., Capp R.H., Davis D.R., Peerless J., and Ravitz L.R. Can nutritional supplements help mentally retarded children? An exploratory study. Proceedings of the National Academy of Science USA 78 1 (1981) 574-578
56. Hibbeln J.R. Fish consumption and major depression. The Lancet 351 (1998) 1213
57. Hibbeln J.R., Umhau J.C., Linnoila M., George D.T., Ragan P.W., Shoaf S.E., et al. A replication study of violent and nonviolent subjects: Cerebrospinal fluid metabolites of serotonin and dopamine are predicted by plasma essential fatty acids. Biological Psychiatry 44 (1998) 243-249
58. Hirayama S., Hamazaki T., and Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder-a placebo-controlled double-blind study. European Journal of Clinical Nutrition 58 (2004) 467-473
59. Holman R.T. The slow discovery of the importance of w3 essential fatty acids in human health. Journal of Nutrition 128 (1998) 427S-433S
60. Hollomon H.A., Dobbins D.R., and Scott K.G. The effects of biological and social risk factors on special education placement: Birth weight and maternal education as an example. Research in Developmental Disabilities 19 3 (1998) 281-294
61. Horrobin D.F. Schizophrenia and membrane lipids. In: Hillbrand M., and Spitz R.T. (Eds). Lipids, health, and behavior (1997), American Psychological Association, Washington, DC 179-194
62. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophrenia Research 30 (1998) 193-208
63. Horrobin D.F. Omega-3 fatty acid for schizophrenia. American Journal of Psychiatry 160 1 (2003) 188-189
64. Horrobin D.F., and Bennett C.N. Depression and bipolar disorder: Relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Prostaglandins, Leukotrienes and Essential Fatty Acids 60 4 (1999) 217-234
65. Hu F.B., Manson J.E., and Willett W.C. Types of dietary fat and risk of coronary heart disease: A critical review. Journal of the American College of Nutrition 20 1 (2001) 5-19
66. Hunt R.D., and Cohen D.J. Attentional and neurochemical components of mental retardation: New methods for an old problem. In: Stark J.A., Menolascino F.J., Albarelli M.H., and Gray V.C. (Eds). Mental retardation and mental health: Classification, diagnosis, treatment, services (1998), Sringer-Verlag, New York 90-97
67. Hwang D.H., Chanmugam P.S., Ryan D.H., Boudreau M.D., Windhauser M.M., Tulley R.T., et al. Does vegetable oil attenuate the beneficial effects of fish oil in reducing risk factors for cardiovascular disease?. American Journal of Clinical Nutrition 66 (1997) 89-96
68. Infante J.P., and Huszagh V.A. Impaired arachidonic (20:4n-6) and docosahexaenoic (22:6n-3) acid synthesis by phenylalanine metabolites as etiological factors in the neuropathology of phenylketonuria. Molecular Genetics and Metabolism 72 (2001) 185-198
69. Iribarren C., Markovitz J.H., Jacobs Jr. D.R., Schreiner P.J., Daviglus M., and Hibbeln J.R. Dietary intake of n-3, n-6 fatty acids and fish: Relationship with hostility in young adults-the CARDIA study. European Journal of Clinical Nutrition 58 (2004) 24-31
70. Ishii T., Takahashi O., Kawamura Y., and Ohta T. Comorbidity in attention deficit-hyperactivity disorder. Psychiatry and Clinical Neurosciences 57 (2003) 457-463
71. Jadad A.R., Boyle M., Cunningham C., Kim M., and Schachar R. Treatment of attention deficit/hyperactivity disorder. Evidence report/technology assessment. No. 11 (1999), Agency for Healthcare Research and Quality, Rockville, Md (AHRG publication no. 00-E005)
72. Johnson C.R., Handen B.L., Lubetsky M.J., and Sacco K.A. Affective disorders in hospitalised children and adolescents with mental retardation: A retrospective study. Research in Developmental Disabilities 16 3 (1995) 221-231
73. Kaplan R.J., and Greenwood C.E. Dietary saturated fatty acids and brain function. Neurochemical Research 23 5 (1998) 615-626
74. Konofal E., Lecendreux M., Arnulf I., and Mouren M.C. Iron deficiency in children with attention-deficit/hyperactivity disorder. Archives of Pediatric & Adolescent Medicine 158 12 (2004) 1113-1115
75. La Malfa G., Notarelli A., Hardoy M.C., Bertelli M., and Cabras P.L. Psychopathology and mental retardation: An Italian epidemiological study using the PIMRA. Research in Developmental Disabilities 18 3 (1997) 179-184
76. Laugharne J.D.E., Mellor J.E., and Peet M. Fatty acids and schizophrenia. Lipids 31 (1996) S163-S165
77. Lauritzen L., Hansen H.S., Jørgensen M.H., and Michaelsen K.F. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Progress in Lipid Research 40 (2001) 1-94
78. Leaf A. Plasma nonesterified fatty acid concentration as a risk factor for sudden cardiac death. Circulation 104 (2001) 744-745
79. Leaf A., and Kang J.X. Omega-3 fatty acids and cardiovascular disease. In: Simopoulos A.P., and Pavlou K.N. (Eds). Nutrition and fitness: Diet, genes, physical activity and health Vol. 89 (2001), Karger, Basel 161-172
80. Ley-Jacobs B.M. DHA: An essential building block of the brain (2003), BL Publications, Temecula, CA
81. Lim S.Y., and Suzuki H. Intakes of dietary docosahexaenoic acid ethyl ester and egg phosphatidylcholine improve maze-learning ability in young and old mice. Journal of Nutrition 130 (2000) 1629-1632
82. Lim S.Y., and Suzuki H. Changes in maze behavior of mice occur after sufficient accumulation of docosahexaenoic acid in brain. Journal of Nutrition 131 (2001) 319-324
83. Lipton M.A., and Mayo J.P. Diet and hyperkinesis-An update. Journal of the American Dietetic Association 83 (1983) 132-134
84. Lubar J.F., Swartwood M.O., Swartwood J.N., and Timmermann D.L. Quantitative EEG and auditory event-related potentials in the evaluation of attention-deficit/hyperactivity disorder: Effects of methylphenidate and implications for neurofeedback training. Journal of Psychoeducational Assessment, ADHD Special (1995) 143-160
85. Maes M., and Smith R.S. Fatty acids, cytokines, and major depression. Biological Psychiatry 43 (1998) 313-314
86. Mann C.A., Lubar J.F., Zimmerman A.W., Miler C.A., and Muenchen R.A. Quantitative analysis of EEG in boys with attention-deficit-hyperactivity disorder: Controlled study with clinical implications. Pediatric Neurology 8 1 (1992) 30-36
87. Martinez M. Docosahexaenoic acid therapy in docosahexaenoic acid-deficient patients with disorders of peroxisomal biogenesis. Lipids 31 (1996) S145-S152
88. Miller M.L., Fee V.E., and Netterville A.K. Psychometric properties of ADHD rating scales among children with mental retardation. I: Reliability. Research in Developmental Disabilities 25 (2004) 459-476
89. Mitchell E.A., Lewis S., and Cutler D.R. Essential fatty acids and maladjusted behaviour in children. Prostaglandins, Leukotrienes and Medicine 12 (1983) 281-287
90. Mitchell E.A., Aman M.G., Turbott S.H., and Manku M. Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clinical Pediatrics 26 8 (1987) 406-411
91. Moriguchi T., Loewke J., Garrison M., Catalan J.N., and Salem Jr. N. Reversal of docosahexaenoic acid deficiency in the rat brain, retina, liver, and serum. Journal of Lipid Research 42 (2001) 419-427
92. Moser H.W., and Moser A.B. Very long-chain fatty acids in diagnosis, pathogenesis, and therapy of peroxisomal disorders. Lipids 31 (1996) S141-S144
93. Moss S. Psychiatric disorders in adults with mental retardation. In: Glidden L.M. (Ed). International review of research in mental retardation Vol. 24 (2001), Academic Press, New York 211-243
94. Mostofsky D.I. Models and methods for studying behaviour in polyunsaturated fatty acid research. Lipids 36 9 (2001) 913-917
95. Pauling L. Orthomolecular psychiatry: Varying the concentrations of substances normally present in the human body may control mental disease. Journal of Nutritional and Environmental Medicine 5 2 (1995) 187-198
96. Pearson D.A., Lachar D., Loveland K.A., Santos C.W., Faria L.P., Azzam P.N., et al. Patterns of behavioural adjustment in mental retardation: Comparison of children with and without ADHD. American Journal on Mental Retardation 105 (2000) 236-251
97. Pearson D.A., Santos C.W., Roache J.D., Casat C.D., Loveland K.A., Lachar D., et al. Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 43 (2003) 677-685
98. Peet M. Eicosapentaenoic acid in the treatment of schizophrenia and depression: Rationale and preliminary double-blind clinical results. Prostaglandins, Leukotrienes and Essential Fatty Acids 69 (2003) 477-485
99. Peet M. International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: An ecological analysis. British Journal of Psychiatry 184 (2004) 404-408
100. Peet M. Nutrition and schizophrenia: Beyond omega-3 fatty acids. Prostaglandins, Leukotrienes and Essential Fatty Acids 70 (2004) 417-422
101. Peet M., and Horrobin D.F. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatric Research 36 (2002) 7-18
102. Peet M., Murphy B., Shay J., and Horrobin D.F. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressed patients. Biological Psychiatry 43 (1998) 315-319
103. Phelps L., Brown R.T., and Power T.J. Mental retardation and autistic spectrum disorders. In: Phelps L., Brown R.T., and Power T.J. (Eds). Pediatric psychopharmacology: Combining medical and psychosocial interventions (2002), American Psychological Association, Washington, DC 133-161
104. Pomerantz J.M. Behavioral health matters: Omega-3 fatty acids and mental health. Drug Benefit Trends 13 6 (2001) 2bh-3bh
105. Puri B.K., and Richardson A.J. Sustained remission of positive and negative symptoms of schizphrenia following treatment with eicosapentaenoic acid. Archives of General Psychiatry 55 2 (1998) 188-189
106. Puri B.K., and Richardson A.J. The effects of olive oil on w3 fatty acids and mood disorders. Archives of General Psychiatry 57 7 (2000) 715
107. Ramakrishnan U., Manjrekar R., Rivera J., Gonzáles-Cossío T., and Martorell R. Micronutrients and pregnancy outcome: A review of the literature. Nutrition Research 19 1 (1999) 103-159
108. Rappley M.D. Attention deficit-hyperactivity disorder. New England Journal of Medicine 352 2 (2005) 165-173
109. Ratnesar S.C., Tapsell L.C., Meyer B.J., Calvert G.D., and Storlien L.H. Increasing n-3 PUFA intakes by dietetic means: A case study involving normal healthy adults in the Illawarra region of NSW. Australian Journal of Nutrition and Dietetics 57 2 (2000) 98-103
110. Riccio C.A., Hynd G.W., Cohen M.J., and Gonzalez J.J. Neurological basis of attention deficit hyperactivity disorder. Exceptional Children 60 2 (1993) 118-124
111. Richardson A.J. Clinical trials of fatty acid supplementation in ADHD. In: Glen A.I.M., Peet M., and Horrobin D.F. (Eds). Phospholipid spectrum disorders in psychiatry and neurology (2003), Marius Press, Carnforth 529-541
112. Richardson A.J. Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins, Leukotrienes and Essential Fatty Acids 70 (2003) 383-390
113. Richardson A.J. The role of omega-3 fatty acids in behaviour, cognition and mood. Scandinavian Journal of Nutrition 47 2 (2003) 92-98
114. Richardson A.J., Calvin C.M., Clisby C., Schoenheimer D.R., Montgomery P., Hall J.A., et al. Fatty acid deficiency signs predict the severity of reading and related difficulties in dyslexic children. Prostaglandins, Leukotrienes and Essential Fatty Acids 63 1-2 (2000) 69-74
115. Richardson A.J., Cox I.J., Sargentoni J., and Puri B.K. Abnormal cerebral phospholipid metabolism in dyslexia indicated by phosphorus-31 magnetic resonance spectroscopy. NMR in Biomedicine 10 (1997) 309-314
116. Richardson A.J., and Puri B.K. The potential role of fatty acids in attention-deficit/hyperactivity disorder. Prostaglandins, Leukotrienes and Essential Fatty Acids 63 1-2 (2000) 79-87
117. Richardson A.J., and Puri B.K. A randomised double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Progress in Neuro-Psychopharmacology & Biological Psychiatry 26 (2002) 233-239
118. Richardson A.J., and Ross M.A. Fatty acid metabolism in neurodevelopmental disorder: A new perspective on associations between attention-deficit/hyperactivity disorder, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins, Leukotrienes and Essential Fatty Acids 63 1-2 (2000) 1-9
119. Riemersma R.A. The demise of the n-6 to n-3 fatty acid ratio? A dossier. European Journal of Lipid Science and Technology 103 (2001) 372-373
120. Rowland A.S., Lesesne C.A., and Abramowitz A.J. The epidemiology of Attention-Deficit/Hyperactivity Disorder: A public health view. Mental Retardation and Developmental Disabilities Research Reviews 8 (2002) 162-170
121. Salem Jr. N., Litman B., Kim H.Y., and Gawrisch K. Mechanisms of action of docosahexaenoic acid. Lipids 36 9 (2001) 945-959
122. Schnoll R., Burshteyn D., and Cea-Aravena J. Nutrition in the treatment of attention-deficit hyperactivity disorder: A neglected but important aspect. Applied Psychophysiology and Biofeedback 28 1 (2003) 63-75
123. Silver L.B. The "magic cure": A review of current controversial approaches for treating learning disabilities. American Journal of Disease 140 (1986) 1045-1052
124. Simopoulos A.P. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomedicine and Pharmacotherapy 56 8 (2002) 365-379
125. Simopoulos A.P. Omega-3 fatty acids in wild plants, nuts and seeds. Asia Pacific Journal of Clinical Nutrition 11 S6 (2002) S163-S173
126. Slade M., and Priebe S. Are randomised controlled trials the only gold that glitters?. British Journal of Psychiatry 179 (2001) 286-287
127. Smuts C.M., Huang M., Mundy D., Plasse T., Major S., and Carlson S.E. A randomised trial of docosahexaenoic acid supplementation during the third trimester of pregnancy. Obstetrics and Gynecology 101 3 (2003) 469-479
128. Stevens L.J., Zentall S.S., Abate M.L., Kuczek T., and Burgess J.R. Omega-3 fatty acids in boys with behavior, learning, and health problems. Physiology & Behavior 59 4-5 (1996) 915-920
129. Stevens L.J., Zentall S.S., Deck J.L., Abate M.L., Watkins B.A., Lipp S.R., et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. American Journal of Clinical Nutrition 62 (1995) 761-768
130. Stevens L.J., Zhang W., Peck L., Kuczek T., Grevstad N., Mahon A.K., et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 38 10 (2003) 1007-1021
131. Stoll A.L., Severus W.E., Freeman M.P., Rueter S., Zboyan H.A., Diamond E., et al. Omega-3 fatty acids in bipolar disorder. Archives of General Psychiatry 56 (1999) 407-412
132. Stordy B.J. Dark adaptation, motor skills, docosahexaenoic acid, and dyslexia. American Journal of Clinical Nutrition 71 1 (2000) 323-326
133. Su K.P., Huang S.Y., Chiu C.C., and Shen W.W. Omega-3 fatty acids in major depressive disorder: A preliminary double-blind, placebo-controlled trial. European Neuropsychopharmacology 13 (2003) 267-271
134. Szatmari P., Offord D.R., and Boyle M.H. Ontario child health study: Prevalence of attention deficit disorder with hyperactivity. Journal of Child Psychology and Psychiatry 30 (1989) 219-230
135. Tacconi M.T., Federico C., and Mario S. Brain lipids and diet. In: Hillbrand M., and Spitz R.T. (Eds). Lipids, health and behavior (1997), American Psychological Association, Washington, DC 197-226
136. Tanskanen A., Hibbeln J.R., Tuomilehto J., Uutela A., Haukkala A., Viinamaki H., et al. Fish consumption and depressive symptoms in the general population in Finland. Psychiatric Services 52 4 (2001) 529-531
137. Taylor K.E., Higgins C.J., Calvin C.M., Hall J.A., Easton T., McDaid A.M., et al. Dyslexia in adults is associated with clinical signs of fatty acid deficiency. Prostaglandins, Leukotrienes and Essential Fatty Acids 63 1-2 (2000) 75-78
138. Taylor K.E., and Richardson A.J. Visual function, fatty acids and dyslexia. Prostaglandins, Leukotrienes and Essential Fatty Acids 63 1-2 (2000) 89-93
139. Thatcher R.W. Maturation of the human frontal lobes. Physiological evidence for staging. Developmental Neuropsychology 7 (1991) 397-419
140. Tiemeier H., van Tuijl H.R., Hofman A., Kiliaan A.J., and Breteler M.M. Plasma fatty acid composition and depression are associated in the elderly: The Rotterdam Study. American Journal of Clinical Nutrition 78 1 (2003) 40-46
141. Toren P., Eldar S., Sela B.-A., Wolmer L., Weitz R., Inbar D., et al. Zinc deficiency in attention-deficit hyperactivity disorder. Biological Psychiatry 40 (1996) 1308-1310
142. Uauy R., Peirano P., Hoffman D., Mena P., Birch D., and Birch E. Role of essential fatty acids in the function of the developing nervous system. Lipids 31 (1996) S167-S176
143. Virkkunen M.E., Horrobin D.F., Jenkins D.K., and Manku M. Plasma phospholipid essential fatty acids and prostaglandins in alcoholic, habitually violent, and impulsive offenders. Biological Psychiatry 22 11 (1987) 1087-1096
144. Voigt R.G., Llorente A.M., Jensen C.L., Fraley J.K., Berretta M.C., and Heird W.C. A randomised, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics 139 (2001) 189-196
145. Volkow N.D., Fowler J.S., Wang G., Ding Y., and Gatley S.J. Mechanism of action of methylphenidate: Insights from PET imaging studies. Journal of Attention Disorders 6 Suppl. 1 (2002) S31-S43
146. Wachs T.D. Biomedical and nutritional influences. Necessary but not sufficient: The respective roles of single and multiple influences on individual development (2000), American Psychological Association, Washington, DC 69-96
147. Wainwright P.E. Nutrition and behaviour: The role of n-3 fatty acids in cognitive function. British Journal of Nutrition 83 4 (2000) 337-339
148. Wainwright P.E., Jalali E., Mutsaers L.M., Bell R., and Cvitkovic S. An imbalance of dietary essential fatty acids retards behavioural development in mice. Physiology & Behavior 66 5 (1999) 833-839
149. Wainwright P.E., Xing H.C., Ward G.R., Huang Y.S., Bobik E., Auestad N., et al. Water maze performance is unaffected in artificially reared rats fed diets supplemented with arachidonic acid and docosahexaenoic acid. Journal of Nutrition 129 (1999) 1079-1089
150. Ward P.E. Potential diagnostic aids for abnormal fatty acid metabolism in a range of neurodevelopmental disorders. Prostaglandins, Leukotrienes and Essential Fatty Acids 63 1-2 (2000) 65-68
151. Willats P., and Forsyth J.S. The role of long-chain polyunsaturated fatty acids in infant cognitive development. Prostaglandins, Leukotrienes and Essential Fatty Acids 63 1-2 (2000) 95-100
152. Yehuda S., Rabinovitz S., Carasso R.L., and Mostofsky D.I. Fatty acids and brain peptides. Peptides 19 2 (1998) 407-419
153. Yehuda S., Rabinovitz S., Carasso R.L., and Mostofsky D.I. The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiology of Aging 23 (2002) 843-853
154. Youdim K.A., Martin A., and Joseph J.A. Essential fatty acids and the brain: Possible health implications. International Journal of Developmental Neuroscience 18 4-5 (2000) 383-399
155. Zanarini M.C., and Frankenburg F.R. Omega-3 fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. American Journal of Psychiatry 160 1 (2003) 167-169
156. Zimmer L., Vancassel S., Cantagrel S., Breton P., Delamanche S., Guilloteau D., et al. The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids. American Journal of
157. Zimmerman A.W., Jinnah H.A., and Lockhart P.J. Behavioral Neuropharmacology. Mental Retardation and Developmental Disabilities Research Reviews 4 (1998) 26-35